Home Newsfeeds Guggenheim Downgrades Neoleukin Therapeutics to Neutral

Guggenheim Downgrades Neoleukin Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

EXCLUSIVE: Proof Of Reserves ‘The Only Solution Left’ For Crypto Exchanges To Win Back User Confidence, Says KuCoin CEO

By Mehab Qureshi

November 13, 6:54 PM

Johnny Lyu, the CEO of crypto exchange KuCoin was the first to announce ‘Proof of Reserves,’ after the FTX Token (CRYPTO: FTT)

$DOGE

CytoSorbents Receives $5M In Non-Dilutive Debt Financing From Bridge Bank And Extends Loan Agreement

By Bill Haddad

December 29, 8:01 AM

PRINCETON, N.J., Dec. 29, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery

CTSO

How Do Chipmakers Avoid The China Bans? Nvidia Might Have Something Up Its Sleeve

By Anusuya Lahiri

September 9, 1:37 PM

Mizuho analyst Vijay Rakesh reiterated a Buy and $225 price target on Nvidia Corp (NASDAQ:

AMD

indie Semiconductor Expects Q3 Revenue To Be Above $60M, Slightly Higher Than The Company’s Guidance And Consensus Estimates

By Bill Haddad

October 16, 8:31 AM

Expects Q3 2023 Revenue to be Above $60M and Slightly Higher than Guidance Schedules Q3 Earnings Release and Conference Call for November 9, 2023

INDI

Guggenheim Downgrades Neoleukin Therapeutics to Neutral

Related Posts

EXCLUSIVE: Proof Of Reserves ‘The Only Solution Left’ For Crypto Exchanges To Win Back User Confidence, Says KuCoin CEO

CytoSorbents Receives $5M In Non-Dilutive Debt Financing From Bridge Bank And Extends Loan Agreement

How Do Chipmakers Avoid The China Bans? Nvidia Might Have Something Up Its Sleeve

indie Semiconductor Expects Q3 Revenue To Be Above $60M, Slightly Higher Than The Company’s Guidance And Consensus Estimates